OPA 6566

Drug Profile

OPA 6566

Alternative Names: OPA-6566

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator
  • Developer Acucela; Otsuka Pharmaceutical
  • Class Eye disorder therapies
  • Mechanism of Action Adenosine A2A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Glaucoma; Ocular hypertension

Most Recent Events

  • 14 Jun 2016 Otsuka Pharmaceutical terminates its collaboration agreement with Acucela for OPA 6566 in USA
  • 11 Mar 2016 Otsuka has patent protection for OPA 6566 in USA (Acucela, Form 10-K, March 2016)
  • 21 Sep 2015 OPA 6566 is in phase-I/II development for Glaucoma and Ocular hypertension in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top